FREE WEBINAR: As we move toward the 2030 global elimination goals, the landscape for managing chronic hepatitis B is shifting rapidly. This webinar brings together clinical insights and public health strategy to explore the future of hepatitis B care in New Zealand.
Prof. Gane will cover three critical pillars of modern management:
- The science of a cure: An update on the latest clinical advancements, including the highly anticipated regulatory progress for bepirovirsen, a potential first-in-class treatment aimed at achieving a functional cure.
- Delivering excellence in primary care: A look at optimising the Hepatitis Foundation of New Zealand (HFNZ) model, focusing on how primary care providers can seamlessly integrate monitoring and patient management to ensure no one falls through the cracks.
- The case for a national action plan: A collaborative discussion on the urgent need for a cohesive, nationally funded Hepatitis B Action Plan to streamline diagnosis, improve access to life-saving treatments, and reduce the burden of liver disease across Aotearoa.
Learn how these developments intersect to improve patient outcomes and why a coordinated national strategy is essential for the next chapter of viral hepatitis elimination.
As always, we will answer as many questions as possible.
Presenter
Ed Gane
Ed Gane is Professor of Medicine at University of Auckland and Deputy Director of the New Zealand Liver Transplant Unit.
After training in hepatology and liver transplantation at King’s College Institute of Liver Studies, where he completed a doctorate on hepatitis C, he returned to New Zealand in 1998 to establish the country’s first national liver transplant unit.
In 2007, he founded Auckland Clinical Studies (now New Zealand Clinical Research), which contributed to the development of the first oral cures for hepatitis C and now focuses on finding a finite cure for hepatitis B. Dr Gane has published more than 450 papers and received numerous honours, including the Health Research Council Beaven and Liley Medals, membership in the Order of New Zealand for services to medicine, and New Zealand Innovator of the Year for his work on hepatitis C elimination.
He also chairs the Health New Zealand/Te Whatu Ora oversight committee for hepatitis B and C elimination and serves as clinical advisor for the Hepatitis Foundation of New Zealand hepatitis B surveillance programme.
Supported by an unrestricted educational grant from:
